Show simple item record

Phase II study of nimustine in metastatic soft tissue sarcoma.

dc.contributor.authorWagener, D J
dc.contributor.authorSomers, R
dc.contributor.authorSantoro, A
dc.contributor.authorVerweij, J
dc.contributor.authorWoll, Penella J
dc.contributor.authorBlackledge, G
dc.contributor.authorSchütte, H J
dc.contributor.authorLentz, M A
dc.contributor.authorVan Glabbeke, M
dc.date.accessioned2010-08-02T10:17:45Z
dc.date.available2010-08-02T10:17:45Z
dc.date.issued1991
dc.identifier.citationPhase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma. 1991, 27 (12):1604-5 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid1782068
dc.identifier.urihttp://hdl.handle.net/10541/108783
dc.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.
dc.language.isoenen
dc.subjectLiver Canceren
dc.subjectLung Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukopenia
dc.subject.meshLiver Neoplasms
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNimustine
dc.subject.meshSarcoma
dc.subject.meshThrombocytopenia
dc.titlePhase II study of nimustine in metastatic soft tissue sarcoma.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Radboud University Hospital, Nijmegen, The Netherlands.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.


This item appears in the following Collection(s)

Show simple item record